Description
Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (Monomer, MALS verified) | HLP-H82E3-200ug| Gentaur Distribution US, UK & Europe
TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRHC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRHC peptide of the p53.
Source: Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (HLP-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & HMTEVVRHC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & HMTEVVRHC).
Format: Liquid.
Tag: C-10×His & C-Avi.
Expression System: HEK293.
Expression Region: Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & HMTEVVRHC peptide.
Conjugate: Biotin-labeled.
Molecular Weight: 36.3 kDa and 11.7 kDa.
Characteristics: Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein is produced by co-expression of HLA and B2M loaded with p53 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 38-43 kDa and 12 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity: 95%.
Buffer: PBS, pH7.4.
Storage Conditions: -70℃.
Shipping Conditions: Dry ice
